Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 6765-6772

  Le, H N ^a   Lee, N C ^a   Tsung, K ^a   Norton, J A ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 12;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR MODEL;

EID: 0035892737     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.6765     Document Type: Article

References (39)

1. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
2. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12
3. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
4. Requirement for Vα 14 NKT cells in IL-12-mediated rejection of tumors
5. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells
6. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
7. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes
8. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
9. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells
10. IL-12 induces Th l-directed antitumor response
11. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models
12. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12
13. 8+ tumor-infiltrating lymphocytes
14. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells
15. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
16. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
17. Unique murine tumor-associated antigens identified by tumor-infiltrating lymphocytes
18. T-cell-mediated concomitant immunity to syngeneic tumors. 1. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites
19. The immunological basis of endotoxin-induced tumor regression: Requirement for a pre-existing state of concomitant anti-tumor immunity
20. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue
21. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
22. - αβ T cells in the lungs of euthymic and athymic mice
23. 4+ thymocytes selected by MHC class 1 molecules
24. 2-microglobulin-dependent surface expression of functional mouse CD1.1
25. + T cells and their IFN-γ production in the generalized Shwartzman reaction
26. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
27. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts
28. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells
29. The immunological basis of endotoxin-induced tumor regression: Requirement for T-cell-mediated immunity
30. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
31. + effector T cells
32. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
33. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo
34. Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors even in combination with interleukin-12 treatment: The importance of inducing intratumoral T-cell migration
35. The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-γ-involving host-tumor interaction
36. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
37. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
38. Early events controlling T-helper cell differentiation: The role of the IL-12 receptor
39. Regulation of the interleukin (IL)-12Rβ2 subunit expression in developing T helper I (Th1) and Th2 cells